ES3058680T3 - Cyclohexyl acid isoxazole azines as lpa antagonists - Google Patents
Cyclohexyl acid isoxazole azines as lpa antagonistsInfo
- Publication number
- ES3058680T3 ES3058680T3 ES18830677T ES18830677T ES3058680T3 ES 3058680 T3 ES3058680 T3 ES 3058680T3 ES 18830677 T ES18830677 T ES 18830677T ES 18830677 T ES18830677 T ES 18830677T ES 3058680 T3 ES3058680 T3 ES 3058680T3
- Authority
- ES
- Spain
- Prior art keywords
- methyl
- lpa
- amino
- oxy
- fibrosis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762607398P | 2017-12-19 | 2017-12-19 | |
| PCT/US2018/066111 WO2019126086A1 (en) | 2017-12-19 | 2018-12-18 | Cyclohexyl acid isoxazole azines as lpa antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES3058680T3 true ES3058680T3 (en) | 2026-03-12 |
Family
ID=65003576
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES18830677T Active ES3058680T3 (en) | 2017-12-19 | 2018-12-18 | Cyclohexyl acid isoxazole azines as lpa antagonists |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US11319309B2 (https=) |
| EP (1) | EP3728209B1 (https=) |
| JP (1) | JP7526096B2 (https=) |
| KR (1) | KR102828422B1 (https=) |
| CN (1) | CN111479807B (https=) |
| ES (1) | ES3058680T3 (https=) |
| WO (1) | WO2019126086A1 (https=) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR108838A1 (es) | 2016-06-21 | 2018-10-03 | Bristol Myers Squibb Co | Ácidos de carbamoiloximetil triazol ciclohexilo como antagonistas de lpa |
| ES2898364T3 (es) | 2017-12-19 | 2022-03-07 | Bristol Myers Squibb Co | Acidos carbamoilciclohexílicos ligados a N triazol como antagonistas de LPA |
| JP7299892B2 (ja) * | 2017-12-19 | 2023-06-28 | ブリストル－マイヤーズ スクイブ カンパニー | Ｌｐａアンタゴニストとしてのシクロヘキシル酸ピラゾールアジン |
| EP3853232B1 (en) | 2018-09-18 | 2023-03-01 | Bristol-Myers Squibb Company | Oxabicyclo acids as lpa antagonists |
| ES2946657T3 (es) | 2018-09-18 | 2023-07-24 | Bristol Myers Squibb Co | Acidos ciclopentílicos como antagonistas de LPA |
| CN111434655A (zh) | 2019-01-15 | 2020-07-21 | 武汉朗来科技发展有限公司 | 溶血磷脂酸受体拮抗剂及其制备方法 |
| EP4058144A1 (en) | 2019-11-15 | 2022-09-21 | Gilead Sciences, Inc. | Triazole carbamate pyridyl sulfonamides as lpa receptor antagonists and uses thereof |
| CN114786771A (zh) | 2019-12-12 | 2022-07-22 | 奇斯药制品公司 | 作为lpa受体2抑制剂的喹唑啉衍生物 |
| US20230043672A1 (en) | 2019-12-12 | 2023-02-09 | Chiesi Farmaceutici S.P.A. | Aromatic amido derivatives as lpa receptor 2 inhibitors |
| WO2021116257A1 (en) | 2019-12-12 | 2021-06-17 | Chiesi Farmaceutici S.P.A. | Thienopyrimidine derivatives as lpa receptor 2 inhibitors |
| TWI843503B (zh) | 2020-06-03 | 2024-05-21 | 美商基利科學股份有限公司 | Lpa受體拮抗劑及其用途 |
| EP4161936A1 (en) | 2020-06-03 | 2023-04-12 | Gilead Sciences, Inc. | Lpa receptor antagonists and uses thereof |
| CA3185111A1 (en) | 2020-07-16 | 2022-01-20 | Elisabetta Armani | Amido cyclohexane acid derivatives as lpa receptor inhibitors |
| WO2022174883A1 (en) | 2021-02-16 | 2022-08-25 | Chiesi Farmaceutici S.P.A. | 5-membered heterocyclyl derivatives as dual lpa receptor 1 and lpa receptor 2 inhibitors |
| WO2022174882A1 (en) | 2021-02-16 | 2022-08-25 | Chiesi Farmaceutici S.P.A. | 5-membered heterocyclyl carbamate derivatives as dual lpa receptor 1 and lpa receptor 2 inhibitors |
| CN117043144A (zh) | 2021-03-24 | 2023-11-10 | 奇斯药制品公司 | 作为lpa受体2抑制剂的8-环-取代的喹唑啉衍生物 |
| WO2022240879A1 (en) | 2021-05-11 | 2022-11-17 | Gilead Sciences, Inc. | Lpa receptor antagonists and uses thereof |
| KR20240007233A (ko) | 2021-05-13 | 2024-01-16 | 길리애드 사이언시즈, 인코포레이티드 | Lpa 수용체 길항제 및 이의 용도 |
| WO2023107938A1 (en) | 2021-12-08 | 2023-06-15 | Gilead Sciences, Inc. | Lpa receptor antagonists and uses thereof |
| WO2023118253A1 (en) | 2021-12-23 | 2023-06-29 | Chiesi Farmaceutici S.P.A. | Cyclohexane acid derivatives as lpa receptor inhibitors |
| TW202342017A (zh) | 2022-02-25 | 2023-11-01 | 美商洛子峰生物有限公司 | 用於治療與ｌｐａ受體活性相關的病狀的化合物及組合物 |
| EP4490150A1 (en) | 2022-03-08 | 2025-01-15 | Chiesi Farmaceutici S.p.A. | Amido cyclopropyl derivatives as lpa receptor inhibitors |
| CN119095831A (zh) * | 2022-03-25 | 2024-12-06 | 瓦斯塞拉股份有限公司 | 3-苯基异噁唑衍生物和含有其作为活性成分的用于预防或治疗眼部疾病的药物组合物 |
| WO2026005060A1 (ja) * | 2024-06-28 | 2026-01-02 | 三菱ケミカル株式会社 | 化合物、その化合物の製造方法、その化合物を含む感光性組成物、その組成物を用いたパターン形成方法、基板及び基板の製造方法 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1258484E (pt) | 2000-02-18 | 2009-04-03 | Kyowa Hakko Kirin Co Ltd | Novos compostos de isoxazol e de tiazol e sua utilização enquanto fármacos |
| WO2002062389A1 (en) | 2001-02-08 | 2002-08-15 | Ono Pharmaceutical Co., Ltd. | Remedies for urinary diseases comprising lpa receptor controlling agents |
| JP4692281B2 (ja) | 2003-08-05 | 2011-06-01 | 味の素株式会社 | 新規アゾール化合物 |
| CN102574822A (zh) * | 2009-08-04 | 2012-07-11 | 阿米拉制药公司 | 作为溶血磷脂酸受体拮抗剂的化合物 |
| US8221753B2 (en) | 2009-09-30 | 2012-07-17 | Tracon Pharmaceuticals, Inc. | Endoglin antibodies |
| GB2474748B (en) | 2009-10-01 | 2011-10-12 | Amira Pharmaceuticals Inc | Polycyclic compounds as lysophosphatidic acid receptor antagonists |
| GB2474120B (en) | 2009-10-01 | 2011-12-21 | Amira Pharmaceuticals Inc | Compounds as Lysophosphatidic acid receptor antagonists |
| KR20130126659A (ko) | 2010-12-07 | 2013-11-20 | 아미라 파마슈티칼스 인코포레이티드 | 리소포스파티드산 수용체 길항제 및 섬유증 치료에서의 그의 용도 |
| US8785442B2 (en) | 2011-01-30 | 2014-07-22 | Curegenix, Inc. | Compound as antagonist of lysophosphatidic acid receptor, composition, and use thereof |
| EP2694472B1 (en) | 2011-04-05 | 2020-03-11 | Takeda Pharmaceutical Company Limited | Sulfonamide derivative and use thereof |
| WO2012138648A1 (en) | 2011-04-06 | 2012-10-11 | Irm Llc | Compositions and methods for modulating lpa receptors |
| WO2013070879A1 (en) | 2011-11-10 | 2013-05-16 | Bristol-Myers Squibb Company | Methods for treating spinal cord injury with lpa receptor antagonists |
| US20140329871A1 (en) | 2011-12-04 | 2014-11-06 | Angion Biomedica Corp. | Small molecule anti-fibrotic compounds and uses thereof |
| IN2014DN09352A (https=) | 2012-06-20 | 2015-07-17 | Hoffmann La Roche | |
| JP2015520202A (ja) | 2012-06-20 | 2015-07-16 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | Ｌｐａｒ拮抗薬としてのｎ−アルキルトリアゾール化合物 |
| WO2014145873A2 (en) | 2013-03-15 | 2014-09-18 | Epigen Biosciences, Inc. | Heterocyclic compounds useful in the treatment of disease |
| JP2017095366A (ja) | 2015-11-18 | 2017-06-01 | 持田製薬株式会社 | 新規ビアリールアミド誘導体 |
| AR108838A1 (es) | 2016-06-21 | 2018-10-03 | Bristol Myers Squibb Co | Ácidos de carbamoiloximetil triazol ciclohexilo como antagonistas de lpa |
| ES2898364T3 (es) | 2017-12-19 | 2022-03-07 | Bristol Myers Squibb Co | Acidos carbamoilciclohexílicos ligados a N triazol como antagonistas de LPA |
-
2018
- 2018-12-18 EP EP18830677.3A patent/EP3728209B1/en active Active
- 2018-12-18 US US16/954,552 patent/US11319309B2/en active Active
- 2018-12-18 CN CN201880080917.3A patent/CN111479807B/zh active Active
- 2018-12-18 ES ES18830677T patent/ES3058680T3/es active Active
- 2018-12-18 WO PCT/US2018/066111 patent/WO2019126086A1/en not_active Ceased
- 2018-12-18 JP JP2020533847A patent/JP7526096B2/ja active Active
- 2018-12-18 KR KR1020207020554A patent/KR102828422B1/ko active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3728209A1 (en) | 2020-10-28 |
| CN111479807B (zh) | 2024-11-26 |
| JP2021506878A (ja) | 2021-02-22 |
| EP3728209B1 (en) | 2025-12-24 |
| CN111479807A (zh) | 2020-07-31 |
| WO2019126086A1 (en) | 2019-06-27 |
| KR102828422B1 (ko) | 2025-07-01 |
| US20200317656A1 (en) | 2020-10-08 |
| JP7526096B2 (ja) | 2024-07-31 |
| US11319309B2 (en) | 2022-05-03 |
| EP3728209C0 (en) | 2025-12-24 |
| KR20200100722A (ko) | 2020-08-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES3058680T3 (en) | Cyclohexyl acid isoxazole azines as lpa antagonists | |
| ES2898364T3 (es) | Acidos carbamoilciclohexílicos ligados a N triazol como antagonistas de LPA | |
| ES2936517T3 (es) | Triazol azinas de ácido ciclohexílico como antagonistas de LPA | |
| ES2962367T3 (es) | Acidos carbamoil ciclohexílicos N-enlazados a pirazol como antagonistas de receptores del ácido lisofosfatídico (LPA) | |
| ES2938863T3 (es) | Triazol azoles de ácido ciclohexilo como antagonistas de ácido lisofosfatídico (LPA) | |
| US11261180B2 (en) | Cyclohexyl acid isoxazole azoles as LPA antagonists | |
| ES3054967T3 (en) | Triazole carboxylic acids as lpa antagonists | |
| US11447475B2 (en) | Isoxazole N-linked carbamoyl cyclohexyl acids as LPA antagonists | |
| CN112041302B (zh) | 作为lpa拮抗剂的吡唑o-连接的氨基甲酰基环己基酸 | |
| EP3852746B1 (en) | Cyclopentyl acids as lpa antagonists | |
| US11312706B2 (en) | Cyclohexyl acid pyrazole azines as LPA antagonists | |
| EP3986553B1 (en) | Cyclobutyl carboxylic acids as lpa antagonists | |
| US11352345B2 (en) | Cyclohexyl acid pyrazole azoles as LPA antagonists | |
| ES2948793T3 (es) | Acidos cicloheptílicos como antagonistas de LPA | |
| BR112020011776B1 (pt) | Ácidos de carbamoil ciclo-hexila n-ligados a triazol como antagonistas de lpa, composição e usos |